Initial Prostate Cancer Diagnosis
For patients initially diagnosed with prostate cancer before any treatment
INITIAL PROSTATE CANCER DIAGNOSIS
Doctors use disease features including (but not limited to) those listed below to determine prostate cancer risk group.
Very Low Risk
Patients with an initial diagnosis of PSA less than 10, Gleason 6/Grade Group 1, and less than 3 biopsy cores positive for cancer. Cancer found by needle biopsy and cannot be felt during exam.
Low Risk
Patients with an initial diagnosis of PSA less than 10, Gleason 6/Grade Group 1. Cancer involves one half of one side of the prostate or less.
Intermediate Risk (Favorable)
Patients with an initial diagnosis that includes one of the following: Gleason 7/Grade Group 2, PSA 10-20, or cancer involves more than one-half of one side of the prostate or involves both sides of the prostate.
Intermediate Risk (Unfavorable)
Patients with an initial diagnosis of Gleason 7/Grade Group 3 or that includes 2 or 3 of the following: Gleason 7/Grade Group 2, PSA 10-20, cancer involves more than one-half of one side of the prostate or involves both sides of the prostate.
High Risk
Patients with an initial diagnosis that includes one of the following: PSA more than 20, Gleason 8-9/Grade Group 4-5, tumor has spread a little outside the prostate.
Very High Risk
Patients with an initial diagnosis that includes one of the following: Gleason 9-10/Grade Group 5, tumor has spread to nearby organs.
Regional Risk
Patients with an initial diagnosis of cancer spread to nearby lymph nodes – Regional (Stage 4A); Any PSA, Gleason/Grade Group.
IMPORTANT:
This information is provided for educational purposes only to support patients in understanding and discussing appropriate treatment options with their doctors. Included is information from treatment guidelines for doctors and other sources. However, this information should not be considered as patient treatment guidelines or recommendations, but as educational materials only. Patients should discuss treatments identified herein with their doctors to understand the risks and benefits of each based on their personal diagnosis. Treatment decisions should only be made between the patient and his doctor.
